Watson Sues FDA on Generic Diabetes Drug Ruling

Generic drugmaker Watson Pharmaceuticals sued the U.S. Food and Drug Administration, challenging a ruling against Watson's generic version of a big-selling diabetes drug, Actos.

Watson said that the FDA improperly denied the company's shared exclusivity on the generic version despite Watson directly following directions received from the regulator.

As a result of the FDA's decision, approval could be delayed for up to six months, Watson said in a statement.

Watson planned to launch its generic version of Takeda Pharmaceutical's Actos on Aug. 17 after a 2010 settlement with the Japanese drugmaker.

The first company that files for approval of a generic version of an off-patent drug typically gets marketing exclusivity for 180 days.

An FDA spokeswoman said the agency would not comment on ongoing litigation.

Actos had total U.S. sales of about $2.7 billion for the twelve months ending May 31, Watson said, quoting IMS Health data.

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.